General information about company

Scrip code*543213
NSE Symbol*ROSSARI
MSEI Symbol*NOTLISTED
ISIN*INE02A801020
Name of companyROSSARI BIOTECH LIMITED
Type of companyMain Board
Class of securityEquity
Date of start of financial year01-04-2025
Date of end of financial year31-03-2026
Date of board meeting when results were approved19-07-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange11-07-2025
Description of presentation currencyINR
Level of roundingMillions
Reporting TypeQuarterly
Reporting QuarterFirst quarter
Nature of report standalone or consolidatedConsolidated
Whether results are audited or unaudited for the quarter endedUnaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment ReportingSingle segment
Description of single segmentManufacturing of Specialty Chemicals for Textile, Home and Personal Care, Performance Chemicals and Animal Health and Nutrition industries
Start date and time of board meeting19-07-2025 17:45
End date and time of board meeting19-07-2025 18:45
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualificationNot applicable



Financial Results – Ind-AS

Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-04-202501-04-2025
Date of end of reporting period30-06-202530-06-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedConsolidatedConsolidated
Part IBlue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1Income
Revenue from operations5437.165437.16
Other income1212
Total income5449.165449.16
2Expenses
(a)Cost of materials consumed3343.993343.99
(b)Purchases of stock-in-trade289.57289.57
(c)Changes in inventories of finished goods, work-in-progress and stock-in-trade79.9279.92
(d)Employee benefit expense 374.65374.65
(e)Finance costs57.2857.28
(f)Depreciation, depletion and amortisation expense177.49177.49
(g)Other Expenses
1Other Expenses670.48670.48
Total other expenses670.48670.48
Total expenses4993.384993.38
3Total profit before exceptional items and tax455.78455.78
4Exceptional items 00
5Total profit before tax455.78455.78
6Tax expense
7Current tax161.05161.05
8Deferred tax-36.02-36.02
9Total tax expenses125.03125.03
10Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement00
11Net Profit Loss for the period from continuing operations330.75330.75
12Profit (loss) from discontinued operations before tax00
13Tax expense of discontinued operations00
14Net profit (loss) from discontinued operation after tax00
15Share of profit (loss) of associates and joint ventures accounted for using equity method5.215.21
16Total profit (loss) for period335.96335.96
17Other comprehensive income net of taxes-1.06-1.06
18Total Comprehensive Income for the period334.9334.9
19Total profit or loss, attributable to
Profit or loss, attributable to owners of parent335.96335.96
Total profit or loss, attributable to non-controlling interests00
20Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent-1.06-1.06
Total comprehensive income for the period attributable to owners of parent non-controlling interests00
21Details of equity share capital
Paid-up equity share capital110.73110.73
Face value of equity share capital22
22Reserves excluding revaluation reserve
23Earnings per share
iEarnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations6.076.07
Diluted earnings (loss) per share from continuing operations6.066.06
iiEarnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations00
Diluted earnings (loss) per share from discontinued operations00
iiiEarnings per equity share (for continuing and discontinued operations)
Basic earnings (loss) per share from continuing and discontinued operations6.076.07
Diluted earnings (loss) per share from continuing and discontinued operations6.066.06
24Debt equity ratioTextual Information( 1)
25Debt service coverage ratioTextual Information( 2)
26Interest service coverage ratioTextual Information( 3)
27Disclosure of notes on financial resultsTextual Information(4)

Text Block

Textual Information(4)Notes:1.The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 19th July, 2025.2.The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standard Ind AS 34 on Interim Financial Reporting as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India in terms of Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, as amended.3.The consolidated financial results include the financial results of three foreign subsidiaries Rossari Global DMCC, Rossari Bangladesh Limited, Rossari International Company Limited, two step down foreign subsidiaries Rossari Biotech Trading FZE and Unistar Thai Co. Ltd., 100% subsidiary of Rossari Global DMCC, four Indian subsidiaries Unitop Chemicals Private Limited, Tristar Intermediates Private Limited, Buzil Rossari Private Limited and Rossari Consumer Products Private Limited, an associate company Romakk Chemicals Private Limited and a joint venture company Hextar Unitop SDN. BHD. a joint venture company of Unitop Chemicals Private Limited.4.The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Group considers it as one operating segment.5.The figures for the quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.6.During the quarter ended 30th June, 2025, the Parent Company has allotted 2,825 equity shares of Rs. 2.00 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan 2019.7.Previous year period figures have been regrouped to make them comparable with the current year period figures, which are not material.
For ROSSARI BIOTECH LIMITED
EDWARD MENEZES
Executive Chairman
DIN 00149205
Place Mumbai
Date 19th July,2025



Other Comprehensive Income

Date of start of reporting period01-04-202501-04-2025
Date of end of reporting period30-06-202530-06-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedConsolidatedConsolidated
Other comprehensive income [Abstract]
1Amount of items that will not be reclassified to profit and loss
1Remeasurements of the defined benefit plans-3.10-3.10
Total Amount of items that will not be reclassified to profit and loss-3.10-3.10
2Income tax relating to items that will not be reclassified to profit or loss -0.78-0.78
3Amount of items that will be reclassified to profit and loss
1Exchange difference on translation of foreign operations1.261.26
Total Amount of items that will be reclassified to profit and loss1.261.26
4Income tax relating to items that will be reclassified to profit or loss 0.000.00
5Total Other comprehensive income-1.06-1.06